Researchers developed an AAV8-sTβRII hydrogel delivery system that reduced late-stage fibrosis and skin scarring in a gene therapy framework combining biomaterials with targeted genetic modulation. The approach uses a poly-(HA-GMA) hydrogel as a delivery matrix aimed at modulating fibrosis pathways without disrupting early wound-healing processes. The key mechanistic goal is to target the later fibrotic phase of healing—where scars consolidate—while preserving early repair biology, a longstanding challenge for anti-scarring interventions. By embedding viral delivery within a hydrogel scaffold, the system aims to localize effect and potentially improve therapeutic consistency. For developers, the work reinforces that delivery engineering is increasingly as important as target selection in dermatology gene therapies, especially when the endpoint depends on tissue remodeling over time. If these preclinical findings translate, the platform could broaden the design space for scar prevention in procedures where fibrosis is a primary driver of long-term morbidity.